Results 301 to 310 of about 106,395 (322)
Some of the next articles are maybe not open access.
Cyclooxygenase-2 Inhibitors in Glioma Therapy
American Journal of Therapeutics, 2004The cyclooxygenase enzyme is a prostaglandin synthase that has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Upregulation of the COX-2 isoform in many cancers has led to investigation regarding the potential role of this enzyme in oncogenesis.
Victor A. Levin, Pierre Giglio
openaire +3 more sources
The Cyclooxygenase-2 Inhibitors: Safety and Effectiveness
Annals of Pharmacotherapy, 1999OBJECTIVE: To review the development of cyclooxygenase-2 (COX-2) inhibitors and discuss specific agents that are currently under investigation or have been marketed. DATA SOURCES: Primary literature on selective COX inhibitors was identified from a comprehensive MEDLINE, English-literature search from January 1966 through September 1998, with ...
Barbara Storyk Klostermeyer +1 more
openaire +2 more sources
Selective inhibitors of cyclooxygenase-2
Expert Opinion on Therapeutic Patents, 1997Prostaglandins (PGs) produced by the inducible enzyme cyclooxygenase-2 (COX-2) are important mediators of pain and inflammation. In animals, selective inhibitors of COX-2 have been shown to be anti-inflammatory without typical non-steroidal anti-inflammatory drug (NSAID) side-effects. Research directed towards the identification of potent and selective
openaire +2 more sources
ChemInform Abstract: Enantiospecific, Selective Cyclooxygenase‐2 Inhibitors
ChemInform, 2002AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Lawrence J. Marnett +3 more
openaire +4 more sources
Cardiovascular effects of cyclooxygenase-2 inhibitors
Current Opinion in Internal Medicine, 2008Arthritis and musculoskeletal disorders are highly prevalent and management often involves the use of nonsteroidal antiinflammatory drugs. Cyclooxygenase-2 enzyme inhibitors are newer selective nonsteroidal antiinflammatory drugs that purport to exhibit less gastrointestinal toxicity than traditional nonsteroidal antiinflammatory drugs.
openaire +3 more sources
Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry, 2007Cyclooxygenase is a key enzyme responsible for metabolisation of arachidonic acid into prostaglandins and thromboxane. This enzyme is the target of non steroidal anti-inflammatory drugs (NSAIDs), used against inflammation and pain. The inducible COX-2 was associated with inflammatory conditions, whereas the constitutive form (COX-1) was responsible for
J. Dogné +4 more
openaire +5 more sources
Cyclooxygenase-2 inhibitors and cardiovascular risk
Current Opinion in Cardiology, 2006Cyclooxygenase-2 inhibitors, or coxibs, designed to provide comparable pain relief to traditional nonsteroidal anti-inflammatory drugs with reduced risk of gastrointestinal complications, have come under substantial recent scrutiny because of an increased likelihood of adverse cardiovascular events associated with their use.Data concerning the ...
openaire +3 more sources
Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia
Current Opinion in Supportive & Palliative Care, 2008Cancer cachexia is increasingly becoming a critical component in the comprehensive approach to cancer patients influencing morbidity, mortality and quality of life. Therefore its pathophysiology and the main contributing factors have been investigated with the aim of developing effective therapies.
Mantovani G, MADEDDU, CLELIA
openaire +4 more sources
Cyclooxygenase-2 Inhibitor Celecoxib:
Southern Medical Journal, 2000Gastrointestinal side effects from nonsteroidal anti-inflammatory drugs (NSAIDs) result mainly from inhibition of the enzyme cyclooxygenase (COX)-1; it is responsible for the synthesis of prostaglandin E2, which leads to increased mucosal blood flow, increased bicarbonate secretion, and mucus production, thus protecting the gastrointestinal mucosa.
J D, Linder +3 more
openaire +2 more sources
Cyclooxygenase-2–specific inhibitors: are they safe?
The American Journal of Medicine, 2001The basic tenet of the cyclooxygenase-2 (COX-2) hypothesis rests on the fact that sparing of inhibition of COX-1 should result in greater safety than if both COX isoforms are inhibited. This increase in safety should be most evident in those organs and tissues in which COX-1 alone has important, necessary physiologic functions (e.g., the stomach and ...
openaire +3 more sources